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ECM: Extracellular matrix 
TβRII: TGFβ receptor type II 
TβRII+/-: TβRII heterozygous knockout mice 
 
ABSTRACT 
Prolactinomas are the most frequent functioning pituitary adenomas, and sex differences 
in tumor size, behavior and incidence have been described. These differences have been 
associated with earlier diagnosis in woman, as well as with serum estradiol levels. 
Experimental models of prolactinomas in rodents also show a higher incidence in females, 
and recent findings suggest that gender differences in the transforming growth factor beta 
1 (TGFβ1) system might be involved in the sex-specific development of prolactinomas in 
these models. 
The aim of this review is to summarize the literature supporting the important role of 
TGFβ1 as a local modulator of pituitary lactotroph function and to provide recent evidence 
for TGFβ1 involvement in the sex differences found in prolactinoma development in animal 
models. 
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1. Pituitary tumors are slow growing adenomas accounting for 15% of all intracranial 
neoplasms (Farrell 2006; Melmed 2015), with relatively high prevalence (77 cases per 
100.000) (Daly et al. 2009; Fernandez et al. 2010), which increases up to 20% when 
considering tumors found unexpectedly in autopsies (Ezzat et al. 2015). Despite usually 
presenting as benign tumors, pituitary adenomas can cause several clinical disorders due 
to both hypersecretion of pituitary trophic hormones and excessive tumor growth with a 
compressive mass effect in surrounding tissues, inducing visual impairment, headaches, 
neurological disorders and also hypopituitarism caused by compression and disruption of 
the hypothalamic-pituitary axis (Arafah & Nasrallah 2001; Melmed 2011). 
 
Among hormone-secreting pituitary tumors, prolactinomas (prolactin-secreting tumors 
originated from lactotroph cells) are the most frequent (40%) (Ciccarelli et al. 2005).The 
clinical disorders observed in patients are related to hyperprolactinemia, which mainly 
affects gonadal/reproductive function, inducing amenorrhea (cause of early medical 
consultation in women), hypogonadism, galactorrhea, decreased libido and infertility. 
Large tumors can also cause symptoms associated to the mass effect. 
 
1.1 Gender differences in human pituitary adenomas 
Sexual differences in prolactinoma size, incidence and behavior have been described. The 
prevalence is higher in women during the fertile period (between 20-50 years, when the 
tumor ratio between sexes is estimated to be 10:1), but the frequency balances after the 
fifth decade of life (Colao et al. 2003; Gillam et al. 2006). The hormonal alterations caused 
by hyperprolactinemia in women (menstrual cycle disorders)  lead to earlier clinical 
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evaluation and therefore, women usually present microprolactinomas at the time of 
diagnosis. On the contrary, the clinical manifestation of increased serum prolactin levels in 
men is more polymorphic, the length of the asymptomatic phase is higher than in women, 
and symptoms such as sexual dysfunction or decreased libido are usually underestimated 
which causes a delay in diagnosis (Colao et al. 2003; Pinzone et al. 2000). Thus, men 
generally present symptoms of mass effects due to the presence of macroprolactinomas at 
the time of diagnosis (Delgrange et al. 1997; Khare et al. 2016; Nishioka et al. 2003). 
Nevertheless, delayed diagnosis in men may not be the only explanation for the 
differences in tumor size, since prolactinomas in men tend to be more aggressive, with 
lower rates of surgical cure and higher proliferative indexes, suggesting a sex-specific 
behavior for these tumors (Delgrange et al. 1997; Gillam MP & Molitch ME 2015). 
 
Gender differences in the prevalence, severity, age of onset, and clinical presentation 
have been also described in other types of pituitary adenomas. For instance, Cushing's 
disease presents a remarkable preponderance in females, with a female-to-male ratio of 3-
8:1. However, more severe clinical presentation, with larger adenomas, higher invasion 
rate, and higher recurrence rate have been found in men (Liu et al. 2015; Zilio et al. 2014). 
On the other hand, no gender differences were described in human GH-pituitary 
adenomas, neither in the prevalence nor in the maximal tumor size (Colao et al. 2002). 
Regarding the clinically non-functioning pituitary adenomas (NFs), which are mostly of 
gonadotroph cell origin, even though the prevalence is similar in both sexes, 
macroadenomas are more commonly diagnosed in men and at an older age, compared to 
women. Gender differences in nature and biological behavior in NFs have been suggested 
  
6 
 
because the higher proliferative activity and tumor aggressiveness found in men (Iglesias 
et al. 2017). 
 
Sex differences have also been found in animal models of pituitary adenomas, particularly 
prolactinomas, which represent a great tool to study the sex-specific biology of these 
tumors.  
 
2. Animal models of prolactinomas 
Several animal models of prolactinomas are used to study factors involved in tumor 
development. Although these models do not completely recapitúlate the human disease, 
they provide important tools to study pituitary tumor pathogenesis. All of these models 
share the same characteristics: increased pituitary weight, hyperprolactinemia and 
lactotroph hyperplasia. 
 
It is well known that dopamine, acting through dopamine type 2 receptors (Drd2), is the 
main inhibitor of lactotroph function (Wong et al. 2015). On the other hand, estradiol is the 
main stimulus of lactotroph function acting in both, the hypothalamus inhibiting dopamine 
release, and at the pituitary increasing proliferation and secretion and also reducing the 
inhibitory action of dopamine (Ben Jonathan & Hnasko 2001). Based on this regulation, 
the increase in estradiol stimulus or the decrease in dopamine inhibition were the first tools 
used to induce prolactinomas in animal models: the estrogen-treated rat (Heaney et al. 
  
7 
 
1999; Heaney et al. 2002) and the dopamine receptor type 2 (Drd2) knockout mouse 
(Drd2-/-) (Asa et al. 1999; Kelly et al. 1997). 
 
In addition to the control exerted by dopamine and estradiol on lactotroph function, there 
are a myriad of peptides and growth factors participating in intra-pituitary regulation 
(reviewed in (Freeman et al. 2000)). Based on this fact, additional transgenic mice models 
of prolactinomas were developed (reviewed in (Lines et al. 2016)), such as the 
overexpression of several factors under the control of the PRL promoter, e.g.i) galanin (Cai 
et al. 1999; Perumal & Vrontakis 2003), ii) TGFα (McAndrew et al. 1995a), iii) fibroblast 
growth factor receptor 4 (FGFR4) (Ezzat et al. 2015), iv) nerve growth factor (NGF) 
(Borrelli et al. 1992); the PRL receptor-deficient  mouse (PRLR-/-) (Schuff et al. 2002)), and 
overexpression of human chorionic gonadotropin β subunit (hCGβ+ mice) (Faraoni et al. 
2017; Rulli et al. 2002). All these models have helped to clarify, at least in part, the 
mechanisms involved in prolactinoma development.  
 
2.1 Gender differences in animal models of prolactinomas 
Sexual differences in prolactinoma size, incidence and behavior have been described not 
only in humans, but also in animal models of prolactinoma. In thetransgenicmouse hCGβ+ 
mice, females develop strong hyperprolactinemia and large prolactinomas, while hCGβ+ 
males do not (Faraoni et al. 2017; Rulli et al. 2002). In the trasgenic mouse model with 
overexpression of human TGFα directed to the pituitary lactotrophs, females develop 
pituitary adenomas by the age of 12 months while males developed neither hyperplasia 
nor adenomas (McAndrew et al. 1995b). Similar findings were observed in transgenic mice 
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overexpressing galanin in lactotrophs (Cai et al. 1999); while females develop 
hyperprolactinemia and prolactinomas from 10 months onwards, no differences were 
detected in PRL contentor release between normal and transgenic male mice. In the 
mouse models with overexpression of FGFR4 (Ezzat et al. 2015), overexpression of NGF 
(Borrelli et al. 1992), PRLR-/- mice (Lines et al. 2016) and Drd2-/-mice (Asa et al. 1999; 
Kelly et al. 1997), transgenic mice of both sexes develop lactotroph hyperplasia, however 
the tumor enlargement and the hyperprolactinemia are more pronounced in females.  
 
The participation of ovarian steroids in the sex differences observed in the development of 
prolactinoma is well established. Ovariectomized Drd2-/- female mice, as well as hCGβ+ 
female mice, do not develop prolactinomas. However, hormonal replacement treatment is 
not sufficient to achieved the same tumoral size observed in the intact transgenic females 
(Ahtiainen et al. 2010; Hentges & Low 2002), suggesting the participation of other factors, 
that might be under sex steroid control and deserves furher studies.  
On the other hand, studies performed in the four core genotype model demonstrated that 
some sex differences occur due to sex steroids while others depend on chromosomal sex 
(hormonal vs genetic effects) (Arnold 2009; Arnold & Chen 2009; Carruth et al. 2002), 
hence, we cannot rule out the possibility that chromosomal sex factors could be also 
involved in the sex differences found in prolactinoma development. 
 
2.2 Differences among animal models and human prolactinomas  
As exposed, mice models of prolactinoma share features of exacerbated phenotype 
(hyperpolactinemia and prolactinoma development) in females compared to males. These 
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observations are contrary to those found in humans where men usually present with larger 
and more aggressive adenomas. Even though these differences could be attributed, at 
least partially, to the delayed diagnosis in men vs. women, as it was discussed before, 
species-specific mechanisms accounting for the higher propensity of female mice to 
develop prolactinomas may be involved. One possibility is that the effect of sex hormones, 
as estradiol, plays a more important role in mice vs. humans. In fact, it was demonstrated 
that contrary to what is observed in rats, estrogens have little effect on PRL release in 
humans (Ben Jonathan & Hnasko 2001; Sarkar et al. 1998a). Moreover, estradiol exerted 
distinctive and strain-specific effects on lactotroph function in mice and rats (Sinha & 
Gilligan 1982). In addition, estradiol could be exerting different permissive effects for the 
action of other growth factors in the development of prolactinomas in mice vs. humans.  
Mechanisms underlying strain-specific and gender-specific responses to estradiol remain 
largely unknown, and other intra-pituitary growth factors could be also involved in strain- 
and gender differences found prolactinoma development.  
 
3. Pituitary TGFβ1 system 
Among the growth factors participating in the intra-pituitary regulation of lactotroph 
function, TGFβ1 has received special attention, as it was demonstrated that TGFβ1 
mediates dopamine and estradiol effect on lactotroph physiology (Recouvreux et al. 2011; 
Sarkar et al. 2005). Furthermore, the pituitary TGFβ1 system has been proposed as a 
novel target for the development of new therapies in resistant prolactinomas (Faraoni et al. 
2017; Recouvreux et al. 2012). In addition, sex differences found in the expression and 
activity of pituitary TGFβ1 system were associated with gender differences found in the 
development of prolactinomas (Faraoni et al. 2017; Recouvreux et al. 2012). 
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TGFβ1 is a well-known inhibitor of lactotroph proliferation and prolactin secretion, and both 
TGFβ1 and its receptor TβRII are expressed in lactotrophs (Sarkar et al. 1992; Sarkar et 
al. 1998b). Moreover, the main physiological modulators of lactotroph function, dopamine 
and estradiol, also regulate TGFβ1 and TβRII expression in the pituitary. Whereas 
estradiol decreases the expression of TGFβ1 and stimulates prolactin secretion, dopamine 
up-regulates local TGFβ1 expression and secretion, with a concomitant reduction in 
prolactin release and proliferation rate of lactotrophs (Recouvreux et al. 2013). 
 
The TGFβ biology is complex, and, due to the potent biological activity of the cytokine, its 
synthesis, secretion, storage and activation are tightly regulated. The three TGFβ isoforms 
are synthesized as precursor molecules containing a pro-peptide called the latency-
associated peptide (LAP). Within the trans-Golgi, LAP is processed by furin-like enzymes, 
but remains associated with TGFβ by non-covalent interactions (Annes et al. 2003). In 
addition, within the endoplasmic reticulum, LAP is linked to a latent TGFβ binding protein 
(LTBP) by disulfide bonds. LTBPs belong to a family of large secretory extracellular matrix 
(ECM) proteins. LTBPs are glycoproteins that facilitate the secretion, storage, and 
activation of the TGFβ–LAP complex. The large latent complex (LTBP-LAP-TGFβ) is 
incorporated as component of the extracellular matrix, which acts as a cytokine reservoir. 
Trapped in the ECM, latent TGFβ must undergo a highly regulated process of activation by 
which the mature cytokine is released from its latent complex to enable the active form to 
bind its receptor and signal through the SMAD2/3 signaling pathway (Annes et al. 2003; 
Rifkin 2005). 
  
11 
 
 
Even though several latent TGFβ1 activators have been described (including proteases, 
integrins αvβ6 and αvβ8, thrombospondin-1 (TSP-1), and reactive oxygen species), their 
individual contribution in releasing TGFβ1 from its latent complex in each tissue, and their 
local regulation are still not fully understood (Annes et al. 2003; Annes et al. 2004; 
Yoshinaga et al. 2008).  
 
4. TGFβ1 alterations during prolactinoma development:  
TGFβ1 expression and activity are reduced in different animal models of prolactinomas, 
and TGFβ1 has been postulated to be involved in tumor development (Faraoni et al. 2017; 
Pastorcic et al. 1995; Recouvreux et al. 2011; Recouvreux et al. 2012; Recouvreux et al. 
2016). In the estrogen-treated rat model forof prolactinoma (Heaney et al. 1999; Heaney et 
al. 2002), chronic estradiol treatment decreases pituitary TGFβ1 and TβRII mRNA and 
protein, together with an increase in prolactin levels (De et al. 1996; Hentges & Sarkar 
2001; Pastorcic et al. 1995; Sarkar et al. 1992). In agreement, pituitary tumorigenesis 
induced by estrogen treatment is greatly accelerated in TβRII heterozygous knockout mice 
(TβRII+/-) where the expression of TβRII is markedly reduced (Shida et al. 1998). On the 
other hand, active and total pituitary TGFβ1 levels, as well as the expression of several 
components of the TGFβ1 system, were also reduced in female pituitaries from Drd2-/- 
mice compared to wild type counterparts (Recouvreux et al. 2011; Recouvreux et al. 
2013). 
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Moreover, we recently described a reduced pituitary TGFβ1 system in another model of 
prolactinoma: mice that overexpress the human chorionic gonadotropin β subunit (hCGβ+ 
mice) (Faraoni et al. 2017; Recouvreux et al. 2011). 
 
Alterations in the pituitary TGFβ1 system have been also observed in human pituitary 
adenomas. It has been described that TGFβ1 and p-Smad3 protein levels gradually 
decreased, while the inhibitory Smad7 protein gradually increased when normal anterior 
pituitaries were compared to noninvasive and invasive pituitary adenomas (Zhenye et al. 
2014), suggesting that the activity of TGFβ signaling would be limited during tumor 
development. A recent report also described a significant down-regulation of the 
TGFβ1/Smad signaling in 12 cases of dopamine resistant prolactinomas compared to 
normal human pituitaries (Li et al. 2015). 
 
These findings support the contention that decreased pituitary TGFβ1 activity is involved in 
the development of prolactinomas. Moreover, this hypothesis was corroborated when a 
pharmacological treatment that restore pituitary TGFβ1 activity was successful in 
recovering the intrapituitary pSMAD2/3 expression, decreasing pituitary tumor size and 
reducing hyperprolactinemia, in two different animal models of prolactinoma (Faraoni et al. 
2017; Recouvreux et al. 2012). Thus, improvement of the local TGFβ1 biological activity is 
associated with the inhibition of prolactinoma growth. 
 
5. Sex differences in the pituitary TGFβ1 system in animal models of prolactinoma.  
  
13 
 
The presence of sex differences in the pituitary TGFβ1 system was described for the first 
time in the Drd2-/- mice model of prolactinoma (Recouvreux et al. 2013). Male mice 
express more robust levels of pituitary TGFβ1 system components than females, including 
active TGFβ1 levels, and the expression of TβRII, LTBPs and many TGFβ1 activators 
(TSP1, KLK1, MMP2, MT1-MMP, integrins αvβ6 and αvβ8). These results suggest that 
TGFβ1 could be protective in males by restraining excessive lactotroph proliferation and 
prolactin secretion (Figure 1). 
The expression of higher levels of several components of the TGFβ1 system in male 
pituitaries could be attributed to the lower serum estradiol levels present in males, as it 
was demonstrated that estradiol negatively controls most of the components of the system 
(Recouvreux et al. 2013).  
 
Gender differences in dopaminergic and estradiol effects at the pituitary level were 
described several years ago. It is well known that the concentration of dopamine in the 
median eminence of female rats in diestrus is 7 times higher than in males (Gudelsky & 
Porter 1981). On the other hand, basal tuberoinfundibular dopaminergic system (TIDA) 
activity is five times higher in females than in males (Freeman et al. 2000). In agreement 
with these sex divergences in the dopaminergic regulation of lactotroph function, the loss 
of dopamine action through Drd2 disruption (Drd2-/- mice model) has a stronger effect in 
female than in male mice (Diaz-Torga et al. 2002; Saiardi et al. 1997). Although in Drd2-/- 
mice both female and male pituitaries are devoid of dopamine inhibitory control, females 
develop higher hyperprolactinemia than males from 2 months onwards, and while in 
females lactotroph hyperplasia is observed at 6 months, Drd2-/-males only develop pituitary 
lactotroph adenomas at 17 to 20 months of age (Asa et al. 1999).  
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Interestingly, the loss of dopamine action also has a stronger effect in the pituitary TGFβ1 
system in females than in males. Active and total TGFβ1 levels are reduced in Drd2-/- 
female pituitaries compared to wild-type, highlighting the stimulatory role of dopamine on 
pituitary TGFβ1 system (Recouvreux et al. 2011; Recouvreux et al. 2013). Concomitantly, 
downregulation of several putative TGFβ1 activators (as TSP1, MMP2, MMP9, MT1-MMP, 
and tissue kallikrein), as well as the decreased expression of TGFβ1 target genes, TGFβ 
receptor and LTBPs, was observed in Drd2-/- females vs. their wild-type counterparts. 
However, the disruption of dopaminergic inhibition did not affect these parameters in male 
pituitaries. These results demonstrated, for the first time, a gender difference in the 
dopaminergic regulation of the pituitary TGFβ1 system (Figure 2). 
 
Similar observations of the link between sex differences in the TGFβ1 system and 
prolactinoma development were recently described in the mice model of hCGβ 
overexpression (Faraoni et al. 2017), in which only hCGβ+ females develop 
prolactinomas. The pituitary hyperplasia becomes evident in females from 2 months of age 
onwards, and progresses to adenoma by the age of 8-10 months, concomitant with severe 
hyperprolactinemia (Rulli et al. 2002). Because of the high levels of circulating hCG, the 
ovaries of hCGβ+ females present massive luteinization, and progesterone becomes the 
main steroid hormone produced; however, serum estradiol remains at physiological levels.  
In this model TGFβ1 levels (active and total cytokine), as well as TGFβ1 target genes, 
TGFβ receptor, LTBPs, Smad4 and Smad7 expression, were found decreased in hCGβ+ 
female pituitaries compared to their wild-type counterparts. However, no differences in the 
pituitary TGFβ1 system were found between the transgenic and wild-type male pituitaries.  
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On the other hand, a stronger TGFβ1 system was observed in male pituitaries and this fact 
could protect them from excessive lactotroph proliferation (Faraoni et al. 2017) (Figure 1). 
Once more, the sex differences in the regulation of the pituitary TGFβ1 system correlate 
with gender differences in the incidence of prolactinoma. 
 
It is worth to mention that the sexual differences in pituitary TGFβ1 described here have 
been only studied in animal models of prolactinoma. Whether these differences are also 
occurring in human pituitary tumors and whether they can account for sexual differences in 
tumor incidence and/or behavior in humans remain to be studied. 
 
There is a critical relationship between sex steroids and dopamine tone in regulating 
lactotroph function. The balance between estradiol and dopamine is an important factor in 
regulating pituitary TGFβ1 function. The recent findings on sex divergences in the control 
of the pituitary TGFβ1 system by dopamine and estradiol suggest the involvement of local 
TGFβ1 in gender-related differences found in the control of lactotroph function in animal 
models. 
 
Summarizing, sex differences were observed in the regulation of the pituitary TGFβ1 
system in animal models of prolactinoma. In males, the increased cytokine activity and 
increased levels of most of the pituitary TGFβ1 system components could be protective 
from excessive lactotroph proliferation and prolactinoma development. On the other hand, 
when dopaminergic regulation is lost, the pituitary TGFβ1 system is deeply affected in 
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females, but not in males, and this could also account for the gender divergences in 
prolactinoma incidence in the animal models (Figure 2). 
It would be worth determining whether sexual differences in pituitary TGFβ1 system are 
also found in humans, and if they are involved in the differences found in prolactinoma 
incidence during fertile period. 
 
Funding: This work was supported by the Agencia Nacional de Promoción Científica y 
Técnica, Buenos Aires, Argentina (grant PICT N2136 to GDT), CONICET, Argentina (PIP 
183 to SBR) and René Barón Fundation (to GDT and SBR). 
 
Figure Legends 
Figure 1. Sex differences in pituitary TGFβ1 system in mice models of prolactinomas. 
TGFβ1 is a potent suppressor of lactotroph proliferation and prolactin secretion. In the 
Drd2 -/- and hCGβ+ mice models of prolactinoma, males present higher levels of active 
TGFβ1, and higher expression of TβRII receptor, LTBPs, and TGFβ1 activators compared 
to females. Increased levels the pituitary TGFβ1 system components, could be protective 
from excessive lactotroph proliferation and prolactinoma development. Modified from 
Recouvreux et al,  J Endocrinol. 2016; 228(3):R73-83. doi: 10.1530/JOE-15-0451 .  
 
Figure 2. Gender differences in the pituitary TGFβ1 system, and its regulation by estradiol 
(E2) and dopamine (DA). Males present a more robust pituitary TGFβ1 system compared 
to females (see Figure 1), which is proposed to have a protective effect, restraining 
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excessive lactotroph proliferation and prolactin secretion. Estradiol exerts a negative 
control on the expression of several components of the pituitary TGFβ1 system, possibly 
accounting for the observed gender differences. On the other hand, dopamine positively 
regulates pituitary TGFβ1 in females, therefore, loss of dopamine regulation in Drd2-/- mice 
deeply affects pituitary TGFβ1 system in females but not in males, also accounting for 
gender differences in prolactinoma development in this model. 
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Highlights 
 
• Sex differences in prolactinomas size, behavior and incidence is described. 
• TGFβ1 is an important inhibitor of lactotroph function 
• TGFβ1 activity is reduced in prolactinomas in a sexually dimorphic manner. 
• TGFβ1 involvement in sex differences found in prolactinomas is suggested. 
 
 
 
 
 
